This decrease of 1.61 million year-over-year was primarily due to decrease in expenses related to our Phase III and Phase II clinical trials and a decrease in expenses in connection with stock-based compensation, materials, travel, rent, and other activities.

Apr 25, 2021 / CFO / receipt, needs a key / Preetam Shah, CFO | earnings call 2021-04-25 | transcript 6be62983-8d90-44ae-9af2-371c4b38b631 | chars 11430-11689 | segment 11

A decrease of $1.5 million in proceeds received in connection with treatment of patients under the hospital exemption regulatory pathway, a decrease of approximately 2.6 million in participation of IIA and CIRM in 2020 under various awarded grants, and an increase of approximately 269,000 for costs related to travel, patents, and other costs.

Feb 3, 2020 / CFO / receipt, needs a key / Preetam Shah, CFO | earnings call 2020-02-03 | transcript d0d89e66-b6bc-49ca-9b43-d17937042fe9 | chars 11544-11888 | segment 11

The decrease in expenses was partially offset by an increase in costs related to patents, preclinical R&D activities, travel and consultants, and a decrease in grant participation by the Israel Innovation Authority, or IIA.

Aug 4, 2021 / CFO / receipt, needs a key / Dr. Preetam Shah, CFO | earnings call 2021-08-04 | transcript 5fbc81bb-4424-4246-bbce-9050207c0058 | chars 10694-10917 | segment 10

General and administrative expenses for the three months ended June 30, 2021, were $2.52 million compared to $1.71 million in the three months ended June 30, 2020. This increase of approximately $816,000 year over year was primarily due to an increase in payroll, stock-based compensation, consultants, rent, and other costs, partially offset by a decrease in PR and travel expenses.

Aug 4, 2021 / CFO / receipt, needs a key / Dr. Preetam Shah, CFO | earnings call 2021-08-04 | transcript 5fbc81bb-4424-4246-bbce-9050207c0058 | chars 11126-11509 | segment 11